SCHEMBL1108494

SCHEMBL1108494

C[C@@H](NS(=O)(=O)c1ccc(Oc2ccncc2)cc1)[C@]1(C)NC(=O)NC1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 6/20 0.40
ADAMTS4 O75173 2/20 0.39
MMP9 P14780 4/20 0.39
MMP13 P45452 5/20 0.39
PTGS2 P35354 1/20 0.38
LMNA P02545 2/20 0.38
HTT P42858 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MMP2 P08253 4/20 0.37
POLB P06746 2/20 0.37
MMP3 P08254 2/20 0.37
MMP7 P09237 2/20 0.37
NAMPT P43490 1/20 0.35
GCK P35557 1/20 0.35
TARS1 P26639 1/20 0.34
ADAM17 P78536 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
MMP8 P22894 1/20 0.34
MMP14 P50281 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1108502 1.00 MMP1 (0.40) MMP1ADAMTS4MMP9MMP13PTGS2
SCHEMBL1108501 0.88 MMP9 (0.51) MMP1ADAMTS4MMP9MMP13LMNA
SCHEMBL1108541 0.88 FFAR1 (0.42) MMP1ADAMTS4MMP9MMP13PTGS2
SCHEMBL1108586 0.88 MMP9 (0.51) MMP1ADAMTS4MMP9MMP13LMNA
SCHEMBL1108577 0.88 MMP2 (0.44) MMP1ADAMTS4MMP9MMP13LMNA
SCHEMBL1108557 0.88 FFAR1 (0.42) MMP1ADAMTS4MMP9MMP13PTGS2
SCHEMBL1108587 0.88 MMP2 (0.44) MMP1ADAMTS4MMP9MMP13LMNA
SCHEMBL1108564 0.87 PGR (0.41) MMP1ADAMTS4MMP9MMP13PTGS2
SCHEMBL1108547 0.87 FFAR1 (0.41) MMP1ADAMTS4MMP9MMP13PTGS2
SCHEMBL13127079 0.87 MMP9 (0.40) MMP1ADAMTS4MMP9MMP13LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153673-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2012-04-10 US disclosed
US-8153673-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2012-04-10 US disclosed
US-20100273849-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2010-10-28 US disclosed
US-20100273849-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2010-10-28 US disclosed
US-7666892-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2010-02-23 US disclosed
US-7666892-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2010-02-23 US disclosed
US-20080262045-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-10-23 US disclosed
US-20080262045-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-10-23 US disclosed
US-7368465-B2 Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders ASTRAZENECA AB (SE) 2008-05-06 US disclosed
US-7368465-B2 Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders ASTRAZENECA AB (SE) 2008-05-06 US disclosed
US-20040138276-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-15 US disclosed
US-20040138276-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273849-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP11 MMP1 8/4885ADAMTS4 35/4885MMP9 1/4885
US-20080262045-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP11 MMP1 8/4885ADAMTS4 35/4885MMP9 1/4885
US-20040138276-A1 Metalloproteinase inhibitors MMP9, MMP11, MMP7 MMP1 11/4885ADAMTS4 30/4885MMP9 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.